Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
Outlook Therapeutics (OTLK) announced it has re-submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, ...
Precigen's PRGN-2012 and UltraCAR-Ts offer groundbreaking therapies. Read why PGEN stock is a strong pick, with major ...
We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...
The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
Wa'el Hashad Wa'el Hashad, Chief Executive Officer, Longeveron Inc. Pivotal Phase 2b clinical trial (ELPIS II) evaluating ...
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for ...
Legit on MSN16h
Lady Schooling in Canada Shares Messages She Received from Man in His 40s Whom She RejectedAn international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
The historic twin jubilee celebration, marking the 150th birth anniversary and the 125th priestly ordination of the Servant ...
As a result, cash runway extended into 2028 and includes full execution and topline 52-week data from 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in wet AMD, and ongoing Phase 1 & 2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback